frontiers | Frontiers in Immunology

TYPE Correction
PUBLISHED 16 January 2024
DOI 10.3389/fimmu.2023.1335691

Check for updates

OPEN ACCESS

EDITED AND REVIEWED BY
Stefan Tukaj,
University of Gdansk, Poland

*CORRESPONDENCE
Michael Basler
michael.basler@uni-konstanz.de

RECEIVED 09 November 2023
ACCEPTED 27 December 2023
PUBLISHED 16 January 2024

CITATION
del Rio Oliva M, Mellett M and Basler M (2024) Corrigendum: Immunoproteasome inhibition attenuates experimental psoriasis. *Front. Immunol.* 14:1335691. doi: 10.3389/fimmu.2023.1335691

COPYRIGHT
© 2024 del Rio Oliva, Mellett and Basler. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Corrigendum: Immunoproteasome inhibition attenuates experimental psoriasis

Marta del Rio Oliva [1], Mark Mellett [2,3] and Michael Basler [1,4]*

[1]Division of Immunology, Department of Biology, University of Konstanz, Konstanz, Germany, [2]Department of Dermatology, University Hospital Zürich (USZ), Zürich, Switzerland, [3]Faculty of Medicine, University of Zürich (UZH), Zürich, Switzerland, [4]Biotechnology Institute Thurgau at the University of Konstanz, Kreuzlingen, Switzerland

KEYWORDS

immunoproteasome inhibition, psoriasis, CARD14, imiquimod, ONX 0914

A Corrigendum on:

Immunoproteasome inhibition attenuates experimental psoriasis

by del Rio Oliva M, Mellett M and Basler M (2022) *Front. Immunol.* 13:1075615. doi: 10.3389/fimmu.2022.1075615

In the published article, there was an error in Figure 6 as published. In Figure 6B the representative microscopy images for CD3 IMQ vehicle and IMQ ONX 0914 were mistakenly switched and the representative image for IL-17A IMQ vehicle was incorrectly incorporated. The corrected Figure 6 and its caption appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

10.3389/fimmu.2023.1335691



FIGURE 6
Immunoproteasome inhibition normalizes the weight of dLNs and ameliorates the inflammatory infiltrate in IMQ-induced psoriasis-like inflammation. IL-17A-GFP mice were treated as described in Figure 5A. **(A)** The dLNs and spleens were harvested after 8 days of treatment with IMQ/vaseline. On the γ-axis, the organ weight normalized to the body weight is depicted. Data (vaseline vehicle n = 4-5, IMQ vehicle, and ONX 0914 n = 6) was pooled from two independent experiments and analyzed by a one-way ANOVA followed by a Šidák test. **(B)** Representative images of ear cryosections that were stained with anti-CD3, anti-CD4, anti-CD45, anti-Ki67 antibodies or IL-17A (all in green), and DAPI (in blue). The scale bar is 100 µm **(C)** The positive signal was quantified with ImageJ. On the γ-axis, the ratio of the fluorescence signal to DAPI is depicted. Data (n = 4-6) were pooled from 2 independent experiments and statistically analyzed by unpaired t-test or Mann-Whitney test. All values represent mean ± SD. *p < 0.05, **p <0.01, and ***p < 0.001.